Immune-Boosting drug trial aims to improve cancer surgery outcomes
NCT ID NCT04624399
Summary
This study is testing if a drug called atezolizumab can shrink tumors before surgery for patients with certain cancers of the urinary system (bladder, kidney, or ureter). The drug works by helping the patient's own immune system recognize and attack the cancer cells. Eligible patients will receive two doses of the drug over about six weeks, then have their planned surgery, and be followed for two years to see if the treatment helps.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROGENITAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Barts and London Hospital NHS Trust
RECRUITINGLondon, United Kingdom
Contact
Contact
Conditions
Explore the condition pages connected to this study.